NCT02732639View on ClinicalTrials.gov

A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)

PHASE3CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Hepatitis D, Chronic
Interventions
DRUG

Pegylated Interferon (PEG-IFN) alfa-2a

Participants received pegylated interferon (PEG-IFN) alfa-2a 180 microgram (mcg) subcutaneously (SC) weekly for 48 weeks.

Trial Locations (7)

293406

Timișoara

400162

Cluj-Napoca

700111

Iași

021105

Bucharest

022328

Bucharest

Unknown

Constanța

Craiova

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02732639 - A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD) | Biotech Hunter | Biotech Hunter